11/02/18 Bridge Therapeutics Announces the Addition of Dr. Bob Rappaport to Its Scientific Advisory Board
As their newest member, Dr. Bob Rappaport brings decades of drug approval experience to Bridge Therapeutics’ Scientific Advisory Board.
November 2, 2018
Dr. Rappaport spent 20 years at the Food and Drug Administration, with the last 12 years as Director of the Anesthesia, Analgesia, and Addiction Products Division at the Center for Drug Evaluation and Research. There he oversaw the approvals of drug products for that sector. Prior to his retirement, Dr. Rappaport received the FDA Lifetime Achievement Award.